SK287142B6 - Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie - Google Patents
Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie Download PDFInfo
- Publication number
- SK287142B6 SK287142B6 SK1326-2002A SK13262002A SK287142B6 SK 287142 B6 SK287142 B6 SK 287142B6 SK 13262002 A SK13262002 A SK 13262002A SK 287142 B6 SK287142 B6 SK 287142B6
- Authority
- SK
- Slovakia
- Prior art keywords
- pyrrole
- dihydro
- dimethyl
- carboxylic acid
- indol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Polyurethanes Or Polyureas (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18271000P | 2000-02-15 | 2000-02-15 | |
US21642200P | 2000-07-06 | 2000-07-06 | |
US24353200P | 2000-10-27 | 2000-10-27 | |
PCT/US2001/004813 WO2001060814A2 (fr) | 2000-02-15 | 2001-02-15 | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
Publications (2)
Publication Number | Publication Date |
---|---|
SK13262002A3 SK13262002A3 (sk) | 2003-03-04 |
SK287142B6 true SK287142B6 (sk) | 2010-01-07 |
Family
ID=27391578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1326-2002A SK287142B6 (sk) | 2000-02-15 | 2001-02-15 | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
Country Status (43)
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
EP1147214B1 (fr) | 1999-01-13 | 2011-01-05 | The Research Foundation Of State University Of New York | Nouveau procede d'identification d'inhibiteurs de proteines kinase |
CN1329390C (zh) * | 2000-02-15 | 2007-08-01 | 苏根公司 | 吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂 |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
MY128449A (en) | 2000-05-24 | 2007-02-28 | Sugen Inc | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
CA2410509A1 (fr) | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Derives d'indolinone comme inhibiteurs de phosphatase/proteine kinase |
US6635640B2 (en) | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
CA2432114A1 (fr) * | 2000-12-20 | 2002-07-18 | Sugen, Inc. | Indolinones 4-aryl substituees |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
EP1247809A3 (fr) * | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Dérivés de triazine et leur application comme inhibiteurs de sorbitol-déhydrogénase |
AU2002303892A1 (en) | 2001-05-30 | 2002-12-09 | Jingrong Cui | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
US20050176687A1 (en) * | 2001-06-29 | 2005-08-11 | Alain Moussy | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
ES2453164T3 (es) * | 2001-08-15 | 2014-04-04 | Pharmacia & Upjohn Company Llc | Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones |
AR038957A1 (es) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
EP1436259A1 (fr) | 2001-09-10 | 2004-07-14 | Congxin Liang | Derives de 3-(4,5,6,7-tetrahydroindol-2-ylmethylidene)-2-indolinone comme inhibiteurs de kinases |
US6642232B2 (en) * | 2001-10-10 | 2003-11-04 | Sugen, Inc. | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
EP1444204A4 (fr) * | 2001-10-22 | 2009-11-04 | Univ New York State Res Found | Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
US20030080191A1 (en) * | 2001-10-26 | 2003-05-01 | Allen Lubow | Method and apparatus for applying bar code information to products during production |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20050131733A1 (en) * | 2001-12-17 | 2005-06-16 | Allen Lubow | Sealable individual bar coded packets |
EP1466297A4 (fr) * | 2001-12-17 | 2005-10-19 | Int Barcode Corp | Dedoublement de codes a barres double face servant de code a barres unique |
WO2003057690A1 (fr) | 2001-12-27 | 2003-07-17 | Theravance, Inc. | Derives d'indolinone utilises comme inhibiteurs de la proteine kinase |
CN1308326C (zh) * | 2002-02-15 | 2007-04-04 | 法马西亚和厄普乔恩公司 | 吲哚满酮衍生物的制备方法 |
AU2003233576A1 (en) * | 2002-05-17 | 2003-12-02 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
ITMI20021620A1 (it) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
AU2003264036A1 (en) * | 2002-08-08 | 2004-03-03 | Vanderbilt University | Pi3k antagonists as radiosensitizers |
AU2003259713A1 (en) * | 2002-08-09 | 2004-02-25 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
US20040121407A1 (en) * | 2002-09-06 | 2004-06-24 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/IGF-1 axis |
HN2003000272A (es) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
JP2006510727A (ja) * | 2002-11-15 | 2006-03-30 | エクセリクシス, インク. | キナーゼモジュレーター |
US7452913B2 (en) | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
CN103265477B (zh) | 2003-02-26 | 2017-01-11 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
US7157577B2 (en) * | 2003-03-07 | 2007-01-02 | Sugen Inc. | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors |
US20040266843A1 (en) * | 2003-03-07 | 2004-12-30 | Sugen, Inc. | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) |
JPWO2004080462A1 (ja) * | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | c−Kitキナーゼ阻害剤 |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10334582A1 (de) * | 2003-07-28 | 2005-02-24 | Basf Ag | Verfahren zur Herstellung von Maleinsäureanhydrid |
WO2005023765A1 (fr) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Methode de catalyse de reactions d'amidation au moyen de co2 |
JP4933259B2 (ja) * | 2003-10-02 | 2012-05-16 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ピロール置換インドリノン化合物の塩および多形 |
WO2005037235A2 (fr) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Inhibiteurs du recepteur 1 du facteur de croissance du fibroblaste et methodes therapeutiques associees |
EA012621B1 (ru) | 2003-11-07 | 2009-10-30 | Чирон Корпорейшн | Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
AU2004294981A1 (en) * | 2003-11-26 | 2005-06-16 | The Scripps Research Institute | Advanced indolinone based protein kinase inhibitors |
US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
US20050152943A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
WO2005118543A1 (fr) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | Inhibiteur des kinases et utilisation de cet inhibiteur |
WO2006002422A2 (fr) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Composes utilises pour l'immunopotentialisation |
SE0401790D0 (sv) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
ES2341351T3 (es) * | 2004-08-26 | 2010-06-18 | Pfizer, Inc. | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas. |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
CN100432071C (zh) * | 2004-11-05 | 2008-11-12 | 中国科学院上海药物研究所 | 取代1h-吲哚-2-酮类化合物及其制备方法和用途 |
GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
AU2006227880A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer |
AU2006238930B2 (en) | 2005-04-26 | 2010-12-23 | Pfizer Inc. | P-cadherin antibodies |
BRPI0609957A2 (pt) * | 2005-05-12 | 2010-05-11 | Pfizer | uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer |
ES2405785T3 (es) | 2005-05-18 | 2013-06-03 | Array Biopharma Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
EP2270000B1 (fr) | 2005-05-23 | 2015-07-29 | Novartis AG | Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one |
KR20080017058A (ko) * | 2005-05-26 | 2008-02-25 | 더 스크립스 리서치 인스티튜트 | 향상된 인돌리논계 단백질 키나제 억제제 |
EP1925941B1 (fr) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Procédé de prédiction de l'efficacité d'un inhibiteur de vascularisation |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
PT2447283E (pt) | 2005-09-07 | 2015-10-08 | Pfizer | Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1) |
RU2399619C2 (ru) * | 2005-09-19 | 2010-09-20 | Пфайзер Продактс Инк. | Твердые солевые формы замещенного пирролом 2-индолинона |
KR101353763B1 (ko) * | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
KR20080083341A (ko) * | 2005-12-29 | 2008-09-17 | 더 스크립스 리서치 인스티튜트 | 인돌리논의 아미노산 유도체 기재의 단백질 키나제 억제제 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101007801A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途 |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
MX2008013430A (es) | 2006-04-19 | 2009-01-26 | Novartis Vaccines & Diagnostic | Compuestos de indazol y metodos para la inhibición de cdc7. |
UA91129C2 (ru) | 2006-05-09 | 2010-06-25 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит |
CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
US20080025946A1 (en) | 2006-07-13 | 2008-01-31 | Sivakumar Pallavur V | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
EP2049541B1 (fr) | 2006-08-04 | 2015-09-23 | Takeda Pharmaceutical Company Limited | N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1h-pyrazole-5-carboxamide en tant qu'inhibiteurs de vegfr |
MY148688A (en) | 2006-08-23 | 2013-05-31 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
EP2065372B1 (fr) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
EP2079727B1 (fr) | 2006-09-15 | 2016-02-17 | Xcovery, INC. | Composés inhibiteurs de kinases |
EP2130829A4 (fr) * | 2006-11-06 | 2010-12-01 | Theravalues Corp | Nouveau dérivé d'hydroxyindole |
BRPI0718029A2 (pt) | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
EP2123649B1 (fr) | 2006-12-04 | 2012-02-29 | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. | Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci |
WO2008093855A1 (fr) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Composition destinée au traitement d'un cancer de l'estomac de type indifférencié |
BRPI0807165A2 (pt) | 2007-02-06 | 2014-05-06 | Pfizer | Compostos de 2-amino pirimidina |
EP2138497A4 (fr) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Nouveau composé d'adénine |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
WO2008138184A1 (fr) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases |
WO2008145398A1 (fr) * | 2007-06-01 | 2008-12-04 | Pfizer Italia S.R.L. | Dérivés de la 2-indoline substituée par 4-arylpyrrole, actifs en tant qu'inhibiteurs de protéine kinase |
EP2162445B1 (fr) | 2007-06-05 | 2013-11-27 | Takeda Pharmaceutical Company Limited | Composés hétérobicycliques comme inhibiteurs de kinase |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US20090062368A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched sunitinib |
DK2197878T3 (en) * | 2007-09-06 | 2016-11-14 | Boston Biomedical Inc | FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases |
WO2009047563A1 (fr) | 2007-10-11 | 2009-04-16 | Astrazeneca Ab | Dérivés pyrrolo[2,3-d]pyrimidine comme inhibiteurs de la protéine kinase b |
EP2218712B1 (fr) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combinaison d'une substance antiangiogénique et d'un complexe de platine antitumoral |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
CA2699306A1 (fr) * | 2007-11-21 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Hemi-l-malate de sunitinib, polymorphes et leur preparation, polymorphes de malate de sunitinib racemique, compositions contenant une base de sunitinib et de l'acide malique et leur preparation |
US8389562B2 (en) * | 2007-12-12 | 2013-03-05 | Medichem, S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
PL2690101T3 (pl) | 2007-12-19 | 2015-12-31 | Genentech Inc | 5-anilinoimidazopirydyny i sposoby zastosowania |
US8940771B2 (en) | 2007-12-20 | 2015-01-27 | Novartis Ag | Organic compounds |
ES2387707T3 (es) | 2007-12-21 | 2012-09-28 | Genentech, Inc. | Azaindolizinas y procedimientos de uso |
BRPI0906576A2 (pt) * | 2008-01-29 | 2015-07-07 | Eisai R&D Man Co Ltd | Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer |
EP2090306A1 (fr) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2113248A1 (fr) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide |
CA2713112A1 (fr) * | 2008-02-13 | 2009-08-20 | Ratiopharm Gmbh | Compositions pharmaceutiques comprenant du n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
CN101255154B (zh) * | 2008-02-18 | 2011-09-07 | 靳广毅 | 一种取代的2-吲哚啉酮衍生物和制备方法及其应用 |
US20110112164A1 (en) * | 2008-02-21 | 2011-05-12 | Generics (Uk) Limited | Novel polymorphs and processes for their preparation |
EP2098521A1 (fr) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide |
PL2274303T3 (pl) * | 2008-03-31 | 2013-03-29 | Teva Pharma | Sposoby otrzymywania sunitynibu i jego soli |
US8466190B2 (en) | 2008-04-16 | 2013-06-18 | Natco Pharma Limited | Polymorphic forms of Sunitinib base |
US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
US8829039B2 (en) | 2008-05-23 | 2014-09-09 | Shanghai Institute Of Pharmaceutical Industry | Dihydroindolinone derivatives |
US8263547B2 (en) * | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
WO2009150523A1 (fr) * | 2008-06-13 | 2009-12-17 | Medichem, S.A. | Procédé de préparation d’un sel 2-indolinone malate à substitution 3‑pyrrole |
EP2313396A1 (fr) | 2008-06-23 | 2011-04-27 | Natco Pharma Limited | Procédé de préparation de sunitinib de haute pureté et de ses sels pharmaceutiquement acceptables |
EP2138167A1 (fr) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2009156837A2 (fr) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole |
DE102008031038A1 (de) | 2008-06-30 | 2009-12-31 | Alexander Priv.-Doz. Dr. Dömling | Sutent zur Anwendung in der Organtransplantation |
CA2729745A1 (fr) * | 2008-06-30 | 2010-01-07 | Cylene Pharmaceuticals, Inc. | Composes d'oxindole |
JP2011526892A (ja) | 2008-06-30 | 2011-10-20 | アンジオブラスト システムズ,インコーポレーテッド | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
EP2318364A2 (fr) * | 2008-07-02 | 2011-05-11 | Generics [UK] Limited | Preparation des derives de 2-indolinone substitue par 3-pyrrole |
JP2011527330A (ja) * | 2008-07-10 | 2011-10-27 | ジェネリクス・(ユーケー)・リミテッド | スニチニブリンゴ酸塩の結晶形の調製方法 |
CA2731605A1 (fr) | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib et ses sels et leurs polymorphes |
CN102164913A (zh) | 2008-07-24 | 2011-08-24 | 麦迪凯姆股份公司 | 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式 |
WO2010017541A2 (fr) * | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions et procédés de traitement d'une maladie dégénérative du système nerveux |
WO2010027423A2 (fr) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions d'antagonistes de pd-1 et methodes d'utilisation associees |
AU2009286520A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Crystalline form of sunitinib and processes for its preparation |
EP2328919A2 (fr) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse |
CN102197034A (zh) * | 2008-08-25 | 2011-09-21 | 基因里克斯(英国)有限公司 | 舒尼替尼的新型多晶型物及其制备方法 |
US8961930B2 (en) * | 2008-09-05 | 2015-02-24 | Imperial Innovations Limited | Isatin derivatives for use as in vivo imaging agents |
CA2735900A1 (fr) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Anticorps diriges contre dll4 et leurs utilisations |
WO2010041134A1 (fr) * | 2008-10-10 | 2010-04-15 | Medichem, S.A. | Procédé pour la préparation d'un sel de malate de 2-indolinone substituée par pyrrole en position 3 |
EP2181991A1 (fr) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Nouveaux sels de sunitinib |
EP2186809A1 (fr) | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | Nouvelle forme cristalline du malate de sunitinib |
US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
JP5579619B2 (ja) | 2008-12-01 | 2014-08-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
WO2010076805A2 (fr) | 2009-01-02 | 2010-07-08 | Hetero Research Foundation | Nouveaux polymorphes de malate de sunitinib |
TWI577664B (zh) | 2009-01-16 | 2017-04-11 | 艾克塞里克斯公司 | N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途 |
KR101984053B1 (ko) | 2009-02-05 | 2019-05-30 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
JP2012517426A (ja) | 2009-02-09 | 2012-08-02 | アステックス ファーマシューティカルズ インコーポレイテッド | ピロロピリミジニルaxlキナーゼ阻害剤 |
WO2010098866A1 (fr) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase |
WO2010098888A1 (fr) * | 2009-02-27 | 2010-09-02 | Massachusetts Institute Of Technology | Utilisations de produits chimiques pour moduler la signalisation par gsk–3 pour le traitement d'un trouble bipolaire et autres troubles cérébraux |
WO2010103094A1 (fr) | 2009-03-13 | 2010-09-16 | Cellzome Limited | Dérivés de pyrimidine comme inhibiteurs du mtor |
WO2010108503A1 (fr) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion de l'intégration neuronale dans des greffons de cellules souches neurales |
WO2010118986A1 (fr) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Composés de pyrimidine substitués par fluoro en tant qu'inhibiteurs de jak3 |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
EP2255792A1 (fr) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
EP2264027A1 (fr) * | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Processus pour la préparation de N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
WO2011004200A1 (fr) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Nouveaux dérivés de pyrrole |
FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP2475648A1 (fr) | 2009-09-11 | 2012-07-18 | Cellzome Limited | Composés de pyrimidine ortho-substitués en tant qu'inhibiteurs de jak |
WO2011033472A1 (fr) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Sels de sunitinib |
KR20120102601A (ko) | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Jak 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
WO2011058521A2 (fr) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib |
WO2011061613A1 (fr) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Procédé de préparation de la forme cristalline ii du sel d'acide malique l du sunitinib |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
EP2507237A1 (fr) | 2009-12-03 | 2012-10-10 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr) |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2011095802A1 (fr) | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Procédé hplc pour l'analyse de sunitinib |
WO2011100325A2 (fr) * | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphes de sels de sunitinib |
MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
MX2012009059A (es) | 2010-02-22 | 2012-09-07 | Hoffmann La Roche | Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso. |
WO2011104555A2 (fr) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Nouveau procédé |
US9249129B2 (en) | 2010-03-04 | 2016-02-02 | Cellzome Limited | Morpholino substituted urea derivatives as mTOR inhibitors |
US20130123511A1 (en) | 2010-03-04 | 2013-05-16 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
EP2545034A1 (fr) * | 2010-03-10 | 2013-01-16 | Synthon B.V. | Procédé d'amidation de composés de carboxylate de pyrrole |
WO2011114246A1 (fr) | 2010-03-18 | 2011-09-22 | Ranbaxy Laboratories Limited | Procédé pour la préparation du sel de l'acide maléique du sunitinib |
US9162981B2 (en) | 2010-03-23 | 2015-10-20 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
WO2011128699A2 (fr) * | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Procédés inédits |
KR20130094693A (ko) | 2010-04-30 | 2013-08-26 | 셀좀 리미티드 | Jak 저해제로서의 피라졸 화합물 |
WO2011138565A1 (fr) | 2010-05-05 | 2011-11-10 | Biorebus | Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs |
EP2392324A1 (fr) | 2010-06-01 | 2011-12-07 | Societe De Coordination De Recherches Therapeutiques | Complexes de rhénium et leur utilisation pharmaceutique |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
JP5898074B2 (ja) | 2010-06-25 | 2016-04-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
WO2012000970A1 (fr) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines en tant qu'inhibiteurs de tyk2 |
CN103097418A (zh) | 2010-07-09 | 2013-05-08 | 霍夫曼-拉罗奇有限公司 | 抗神经毡蛋白抗体及使用方法 |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
WO2012022681A2 (fr) | 2010-08-20 | 2012-02-23 | Cellzome Limited | Analogues de la hétérocyclyl pyrazolopyrimidine comme inhibiteurs sélectifs de la jak |
WO2012027716A1 (fr) | 2010-08-27 | 2012-03-01 | Collabrx, Inc. | Procédé pour traiter un mélanome chez des sujets résistants à un inhibiteur de braf |
WO2012042421A1 (fr) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Procédé de traitement de la croissance cellulaire anormale |
AU2010363613B2 (en) | 2010-11-01 | 2015-02-05 | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. | Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles |
WO2012059941A1 (fr) * | 2010-11-04 | 2012-05-10 | Ind-Swift Laboratories Limited | Procédé pour préparation de malate de sunitinib et sels correspondants |
CN103298794A (zh) | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | 作为tyk2抑制剂的吡啶化合物及其氮杂类似物 |
EP2640384A1 (fr) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Présélection de patients pour un traitement thérapeutique fondé sur un état hypoxique, avec des agents sensibles à l'oxygène |
CA2818612C (fr) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Formulations d'agents therapeutiques pour des dispositifs implantes |
AR083868A1 (es) | 2010-12-03 | 2013-03-27 | Lilly Co Eli | Compuestos de oxazol[5,4-b]piridin-5-ilo |
WO2012088522A1 (fr) | 2010-12-23 | 2012-06-28 | Nektar Therapeutics | Conjugués polymère-dés-éthyl sunitinib |
JP6002149B2 (ja) | 2010-12-23 | 2016-10-05 | ネクター セラピューティクス | ポリマー−スニチニブコンジュゲート |
UY33883A (es) | 2011-01-31 | 2012-08-31 | Novartis Ag | Novedosos derivados heterocíclicos |
WO2012112708A1 (fr) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxiques et procédés de préparation |
DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
CN103534241B (zh) | 2011-02-17 | 2015-11-25 | 癌症疗法Crc私人有限公司 | Fak抑制剂 |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
US8630703B2 (en) | 2011-03-09 | 2014-01-14 | Technion Research & Development Foundation Limited | Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination |
CN102115469A (zh) * | 2011-03-21 | 2011-07-06 | 浙江大学 | 吲哚啉-2-酮类衍生物的制备和用途 |
EP2694511A1 (fr) | 2011-04-04 | 2014-02-12 | Cellzome Limited | Dérivés de dihydropyrrolopyrimidine en tant qu'inhibiteurs de la mtor |
MX2013011481A (es) * | 2011-04-08 | 2014-02-17 | Beta Pharma Inc | Nuevos inhibidores de cinasa de proteina de indolinona. |
CA2828946C (fr) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Agent therapeutique pour les tumeurs |
WO2012143320A1 (fr) | 2011-04-18 | 2012-10-26 | Cellzome Limited | Composés (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine comme inhibiteurs de la jak3 |
CN102898402B (zh) * | 2011-04-26 | 2016-01-20 | 北京大学 | 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用 |
EP2714937B1 (fr) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib |
PT3409278T (pt) | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de proteína cinase heterocíclicos |
US20140179664A1 (en) | 2011-07-28 | 2014-06-26 | Cellzome Limited | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors |
WO2013017480A1 (fr) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak |
WO2013017479A1 (fr) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak |
RU2014115476A (ru) | 2011-09-20 | 2015-10-27 | Целльзом Лимитед | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ |
KR20140070616A (ko) | 2011-09-21 | 2014-06-10 | 셀좀 리미티드 | Mtor 저해제로서의 모르폴리노 치환된 우레아 또는 카바메이트 유도체 |
MX341577B (es) | 2011-10-07 | 2016-08-25 | Cellzome Ltd | Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero. |
CN102499917B (zh) | 2011-10-25 | 2014-12-17 | 澳门大学 | 吲哚酮类化合物在制备神经保护药物中的应用 |
BR112014009890A2 (pt) | 2011-10-28 | 2020-10-27 | Novartis Ag | derivados de purina e seu uso no tratamento de doença |
CN103130774B (zh) * | 2011-11-22 | 2016-06-22 | 齐鲁制药有限公司 | 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用 |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
CN104169272A (zh) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | 作为激酶抑制剂的嘧啶-2,4-二胺衍生物 |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
CN102491932A (zh) * | 2011-12-26 | 2012-06-13 | 天津科技大学 | 一种3-吲哚啉酮类衍生物及其制备方法及其应用 |
CN104114550A (zh) | 2012-03-23 | 2014-10-22 | 劳拉斯实验室私人有限公司 | 制备舒尼替尼及其酸加成盐的改进的方法 |
CN104394868A (zh) | 2012-04-20 | 2015-03-04 | 安基生技制药股份有限公司 | 嘌呤类似物的环丙烷羧酸酯 |
CN102653521B (zh) * | 2012-04-27 | 2014-08-06 | 首都师范大学 | 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途 |
PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
DK2844282T3 (da) | 2012-05-04 | 2019-07-15 | Pfizer | Prostata-associerede antigener og vaccine-baserede immunterapiregimener |
RU2630975C2 (ru) | 2012-05-16 | 2017-09-15 | Новартис Аг | Режим дозирования pi-3 киназы |
SG11201408161RA (en) | 2012-06-08 | 2015-01-29 | Sutro Biopharma Inc | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
ES2611788T3 (es) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
US20160009686A1 (en) | 2012-08-17 | 2016-01-14 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
WO2014031566A1 (fr) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxique |
SI3584255T1 (sl) | 2012-08-31 | 2022-05-31 | Sutro Biopharma, Inc | Modificirane aminokisline, ki vsebujejo azido skupino |
WO2014041349A1 (fr) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Pyrimidines ou pyridazines tétrahydropyran-4-yléthylamino- ou tétrahydropyranyl-4-éthyloxy utiles comme inhibiteurs de l'isoprényl-cystéine-carboxy-méthyl-transférase |
WO2014045101A1 (fr) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Dérivés de tétrazolo quinoxaline utilisés comme inhibiteurs de la tankyrase |
US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
US9999680B2 (en) | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
EP2961435B1 (fr) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
EP2970206A1 (fr) * | 2013-03-13 | 2016-01-20 | Boston Biomedical, Inc. | Dérivés de 3-(aryl ou hétéroaryl)méthylèneindolin-2-one en tant qu'inhibiteurs de kinases de la voie des cellules souches cancéreuses pour le traitement de cancer |
AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
CA2905993C (fr) | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Derives de 4-amino-pyrimidinyle-2-amino-phenyle substitues et compositions pharmaceutiques a base de ceux-ci en tant qu'inhibiteurs dejak2 et d'alk2 |
AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
CN104119321B (zh) * | 2013-04-28 | 2017-09-08 | 齐鲁制药有限公司 | 二氢吲哚酮衍生物的二马来酸盐及其多晶型物 |
WO2014185540A1 (fr) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarqueurs pour prédire et évaluer la réponse de sujets atteints de cancer de l'endomètre à des composés à base de lenvatinib |
WO2014194030A2 (fr) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques |
WO2015006555A2 (fr) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation |
FR3008411B1 (fr) * | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
WO2015031604A1 (fr) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Signatures d'expression génique permettant de prédire la réponse d'un sujet à un inhibiteur multikinase et leurs procédés d'utilisation |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
CA2838585A1 (fr) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | Sel de sunitinib d'acide ascorbique |
CA2838587A1 (fr) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | Forme cristalline pure ii de sel d'acide l-malique de sunitinib et procede pour sa preparation |
EP3524262A1 (fr) | 2013-11-01 | 2019-08-14 | Pfizer Inc | Vecteurs d'expression d'antigènes associés à la prostate |
DK3076969T3 (da) | 2013-12-06 | 2021-11-22 | Novartis Ag | Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer |
CN104829596B (zh) * | 2014-02-10 | 2017-02-01 | 石家庄以岭药业股份有限公司 | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 |
CN103923014A (zh) * | 2014-05-05 | 2014-07-16 | 宁夏宝马药业有限公司 | 环肌酸制备方法 |
AU2015301054B2 (en) | 2014-08-08 | 2020-05-14 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US20180000771A1 (en) | 2015-01-13 | 2018-01-04 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
CA2976325C (fr) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Procede de suppression de l'amertume d'un derive de quinoleine |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
WO2016184793A1 (fr) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr |
EP3298021B1 (fr) | 2015-05-18 | 2019-05-01 | Tolero Pharmaceuticals, Inc. | Promédicaments de l'alvocidib à biodisponibilité augmentée |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
KR20180058758A (ko) | 2015-09-22 | 2018-06-01 | 그레이버그 비젼, 인크. | 안구 장애의 치료를 위한 화합물 및 조성물 |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
AU2016347881A1 (en) | 2015-11-02 | 2018-05-10 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
KR20180102069A (ko) | 2015-11-12 | 2018-09-14 | 그레이버그 비젼, 인크. | 요법을 위한 응집성 마이크로입자 |
KR20180104106A (ko) | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법 |
JP2019508405A (ja) | 2016-02-08 | 2019-03-28 | ヴィトリサ セラピューティクス, インコーポレイテッド | 改良された硝子体内半減期を有する組成物およびその使用 |
EP3228630A1 (fr) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combinaison d'un antagoniste d'apeline et inhibiteur de l'angiogenèse pour le traitement du cancer |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018060833A1 (fr) | 2016-09-27 | 2018-04-05 | Novartis Ag | Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha |
US20190255041A1 (en) | 2016-10-28 | 2019-08-22 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
WO2018094275A1 (fr) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
BR112019011284A2 (pt) | 2016-12-05 | 2019-10-22 | Apros Therapeutics Inc | composto, composição farmacêutica, métodos de tratamento de uma condição, de hbv e de câncer, e, uso de um composto. |
JP2020514252A (ja) | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Cdk4/6媒介性がんを治療するための組成物および方法 |
KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
CN106916143B (zh) * | 2017-03-14 | 2019-09-27 | 哈尔滨医科大学 | 一种预防和治疗冠心病的药物及其应用 |
CN110662543A (zh) | 2017-03-23 | 2020-01-07 | 灰色视觉公司 | 用于治疗眼部疾病的药物和组合物 |
MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
EP3658588A1 (fr) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Méthodes d'utilisation d'anticorps anti-cd74 et de conjugués d'anticorps dans le traitement d'un lymphome à cellules t |
WO2019055579A1 (fr) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib |
RU2020111503A (ru) | 2017-09-18 | 2021-10-20 | Сутро Биофарма, Инк. | Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
EP3539536A1 (fr) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i |
WO2020216450A1 (fr) | 2019-04-25 | 2020-10-29 | Synthon B.V. | Composition pharmaceutique comprenant du sunitinib amorphe |
US10857153B2 (en) | 2018-06-04 | 2020-12-08 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
WO2020060944A1 (fr) | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Polythérapies avec des conjugués d'anticorps anti-récepteur du folate |
EP3890749A4 (fr) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer |
TW202038957A (zh) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與激酶抑制劑之組合 |
JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
WO2020191326A1 (fr) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Traitement de la leucémie myéloïde aiguë (aml) après échec du vénétoclax |
CA3129665A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer |
CN113747895A (zh) | 2019-03-22 | 2021-12-03 | 大日本住友制药肿瘤公司 | 包含pkm2调节剂的组合物和用其治疗的方法 |
WO2020227105A1 (fr) | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Conjugués d'anticorps anti-bcma |
CA3137916A1 (fr) | 2019-05-06 | 2020-11-12 | Ichan School Of Medicine At Mount Sinai | Composes heterobifonctionnels en tant qu'agents de degradation de hpk1 |
JP2022545930A (ja) | 2019-08-31 | 2022-11-01 | 上海奕拓醫藥科技有限責任公司 | Fgfr阻害剤とするピラゾール類誘導体及びその調製方法 |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
CN111233841A (zh) * | 2020-03-17 | 2020-06-05 | 湖北扬信医药科技有限公司 | 一种舒尼替尼有关物质及其制备方法和用途 |
WO2023278424A1 (fr) * | 2021-06-28 | 2023-01-05 | The Regents Of The University Of California | Méthodes de traitement et d'amélioration de maladies liées aux lymphocytes t |
CN113717159A (zh) * | 2021-09-16 | 2021-11-30 | 中国药科大学 | 吲哚酮类化合物及其药物组合物、制备方法及用途 |
WO2023081923A1 (fr) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations |
WO2023228095A1 (fr) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Schéma posologique d'un conjugué anticorps anti-cdh6-médicament |
WO2024006542A1 (fr) | 2022-06-30 | 2024-01-04 | Sutro Biopharma, Inc. | Anticorps anti-ror1 et conjugués d'anticorps, compositions comprenant des anticorps anti-ror1 ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-ror1 et de conjugués d'anticorps |
WO2024017372A1 (fr) * | 2022-07-22 | 2024-01-25 | 成都百裕制药股份有限公司 | Dérivé d'indolone et son utilisation |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL104796C (fr) | 1957-08-19 | |||
DE878539C (de) | 1939-08-17 | 1953-06-05 | Hoechst Ag | Verfahren zur Herstellung von Methinfarbstoffen |
BE507136A (fr) | 1950-11-18 | |||
BE553661A (fr) | 1955-12-23 | |||
BE558210A (fr) | 1956-06-08 | |||
NL251055A (fr) | 1959-04-29 | |||
FR1398224A (fr) | 1964-05-06 | 1965-05-07 | Ici Ltd | Procédé de teinture de matières textiles de polyacrylonitrile |
US3308134A (en) | 1965-10-22 | 1967-03-07 | Mcneilab Inc | Spiro(indan-2, 3'-indoline)-1, 2'-diones |
US3551571A (en) | 1967-05-19 | 1970-12-29 | Endo Lab | Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones |
US3564016A (en) | 1968-03-07 | 1971-02-16 | Endo Lab | Method of decarbonylation |
US4070366A (en) | 1968-06-12 | 1978-01-24 | Canadian Patents & Development Limited | Alkylation process |
FR1599772A (fr) | 1968-09-17 | 1970-07-20 | ||
US3922163A (en) | 1970-01-30 | 1975-11-25 | Upjohn Co | Organic compounds and process |
US3715364A (en) | 1970-12-28 | 1973-02-06 | Merck & Co Inc | Nitroimidazole carboxamides |
DE2159363A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Antimikrobielle mittel |
DE2159360A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159361A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159362A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
GB1384599A (en) | 1972-05-04 | 1975-02-19 | Colgate Palmolive Co | Coloured detergent compositions |
US3880871A (en) | 1973-09-27 | 1975-04-29 | Squibb & Sons Inc | Isothiocyanophenyl substituted imidazoles |
US4002643A (en) | 1975-06-27 | 1977-01-11 | Mcneil Laboratories, Inc. | Preparation of β-acyl pyrroles |
US4002749A (en) | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
US4053613A (en) | 1975-09-17 | 1977-10-11 | E. R. Squibb & Sons, Inc. | 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones |
DE2855306A1 (de) | 1978-12-21 | 1980-07-10 | Boehringer Sohn Ingelheim | Mittel zur senkung der herzfrequenz |
GR73560B (fr) | 1979-02-24 | 1984-03-15 | Pfizer | |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4343923A (en) | 1980-08-07 | 1982-08-10 | Armstrong World Industries, Inc. | Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound |
CH646956A5 (de) | 1981-12-15 | 1984-12-28 | Ciba Geigy Ag | Imidazolide. |
EP0095285A1 (fr) | 1982-05-21 | 1983-11-30 | Sumitomo Chemical Company, Limited | Imidazoles-N-acyl, leur préparation et application |
US4493642A (en) | 1982-12-27 | 1985-01-15 | Bogdon Glendon J | Orthodontic device and associated orthodontic method |
DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4489089A (en) | 1983-04-06 | 1984-12-18 | American Cyanamid Company | Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides |
DE3480392D1 (en) | 1983-04-29 | 1989-12-14 | Ciba Geigy Ag | Imidazolides and their use as curing agents for polyepoxides |
DE3415138A1 (de) | 1984-04-21 | 1985-10-31 | Basf Ag, 6700 Ludwigshafen | N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide |
DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4560700A (en) | 1985-02-08 | 1985-12-24 | Merrell Dow Pharmaceuticals Inc. | Pyrrole-3-carboxylate cardiotonic agents |
JPH078851B2 (ja) | 1985-07-29 | 1995-02-01 | 鐘淵化学工業株式会社 | 3−フエニルチオメチルスチレン誘導体 |
US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
WO1993012786A1 (fr) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Derives d'indolinone |
US4853404A (en) | 1986-10-13 | 1989-08-01 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives composition and use |
US5202341A (en) | 1987-03-11 | 1993-04-13 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds having tyrosine kinase inhibiting activity |
US5089516A (en) | 1987-03-11 | 1992-02-18 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity |
EP0304493B1 (fr) | 1987-03-11 | 1992-09-02 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Derives d'hydroxystyrene |
US5043348A (en) | 1987-04-24 | 1991-08-27 | Cassella Aktiengesellschaft | Pyrrolealdehydes, their preparation and their use |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3808071A1 (de) | 1988-03-11 | 1989-09-21 | Basf Ag | Verfahren zur herstellung von acylierten imidazolen |
US4868304A (en) | 1988-05-27 | 1989-09-19 | Iowa State University Research Foundation, Inc. | Synthesis of nitrogen heterocycles |
CA1339784C (fr) | 1988-06-23 | 1998-03-31 | Shinya Inoue | Derives de l'acide pyrrolecarboxylique |
JPH06104658B2 (ja) | 1988-06-23 | 1994-12-21 | 三菱化成株式会社 | ピロールカルボン酸誘導体 |
DE3824658A1 (de) | 1988-07-15 | 1990-01-18 | Schering Ag | N-hetaryl-imidazolderivate |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
US5084280A (en) | 1988-12-15 | 1992-01-28 | Chapman Chemical Company | Wood preservation composition and method |
DE3902439A1 (de) | 1989-01-27 | 1990-08-02 | Basf Ag | Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern |
US5047554A (en) | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
KR930011300B1 (ko) | 1989-07-25 | 1993-11-29 | 다이호오 야꾸힌 고오교오 가부시끼가이샤 | 옥시인돌유도체 |
US5258357A (en) | 1989-10-07 | 1993-11-02 | Basf Aktiengesellschaft | Carboxamides, their preparation and their use as herbicides |
CA2032421A1 (fr) | 1989-12-20 | 1991-06-21 | Mitsubishi Chemical Corporation | Derive du pyrrolecarbaldehyde |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2012634A1 (fr) | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostines pour le traitement des allergies et des affections inflammatoires et cardiovasculaires |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
IT1247509B (it) | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
US5124347A (en) | 1991-07-31 | 1992-06-23 | Warner-Lambert Co. | 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents |
HU219131B (hu) | 1991-10-18 | 2001-02-28 | Monsanto Co. | Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5389661A (en) | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
FR2689397A1 (fr) | 1992-04-01 | 1993-10-08 | Adir | Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments. |
DE4211531A1 (de) | 1992-04-06 | 1993-10-07 | Cassella Ag | Verfahren zur Herstellung von Pyrrolderivaten |
FR2694004B1 (fr) | 1992-07-21 | 1994-08-26 | Adir | Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JP3507124B2 (ja) | 1993-05-26 | 2004-03-15 | 塩野義製薬株式会社 | ベンジリデン誘導体の製造法 |
EP0632102B1 (fr) | 1993-06-28 | 1997-04-02 | Bayer Ag | Coloration de matières synthétiques dans la masse |
US5332736A (en) | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
US5786488A (en) | 1996-11-13 | 1998-07-28 | Sugen, Inc. | Synthetic methods for the preparation of indolyquinones |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
JP3246712B2 (ja) | 1995-11-15 | 2002-01-15 | 株式会社トクヤマ | エテニルアミド化合物の製造方法 |
EP0788890A1 (fr) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Colorants et éléments donneur de colorant pour l'enregistrement par transfert thermique de colorant |
CA2206201A1 (fr) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Derives du pyrazole et leur emploi en pharmacie |
JP2000515529A (ja) | 1996-08-01 | 2000-11-21 | メルクル・ゲーエムベーハー | 細胞質ホスホリパーゼa▲下2▼の阻害剤としてのアシルピロリドンジカルボン酸およびアシルインドールジカルボン酸ならびにその誘導体 |
WO1998050356A1 (fr) * | 1997-05-07 | 1998-11-12 | Sugen, Inc. | Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
CA2314156C (fr) * | 1998-05-29 | 2010-05-25 | Sugen, Inc. | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
PL348817A1 (en) | 1998-12-14 | 2002-06-17 | Cellegy Pharmaceuticals | Compositions and methods for the treatment of anorectal disorders |
JP2002532492A (ja) * | 1998-12-17 | 2002-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | サイクリン−依存性キナーゼ、特にcdk2のインヒビターとしての4−アルケニル(及びアルキニル)オキシドール |
US6284894B1 (en) | 1998-12-18 | 2001-09-04 | Nycomed Imaging As | Preparation of allylic aromatic compounds |
EP1139754A4 (fr) * | 1998-12-31 | 2002-12-18 | Sugen Inc | Composes 3-heteroarylidenyl-2-indolinone utilises pour modulation de l'activite de la proteine kinase et dans la chimiotherapie du cancer |
EP1233943B1 (fr) * | 1999-11-24 | 2011-06-29 | Sugen, Inc. | Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres |
US20020010203A1 (en) * | 1999-12-22 | 2002-01-24 | Ken Lipson | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
CN1329390C (zh) * | 2000-02-15 | 2007-08-01 | 苏根公司 | 吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂 |
MY128449A (en) | 2000-05-24 | 2007-02-28 | Sugen Inc | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
US6635640B2 (en) * | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
CA2432114A1 (fr) * | 2000-12-20 | 2002-07-18 | Sugen, Inc. | Indolinones 4-aryl substituees |
-
2001
- 2001-02-15 CN CNB018072690A patent/CN1329390C/zh not_active Expired - Lifetime
- 2001-02-15 AR ARP010100703A patent/AR034118A1/es active IP Right Grant
- 2001-02-15 CO CO01012068A patent/CO5280092A1/es not_active Application Discontinuation
- 2001-02-15 DE DE60129794T patent/DE60129794T2/de not_active Expired - Lifetime
- 2001-02-15 DE DE122008000002C patent/DE122008000002I1/de active Pending
- 2001-02-15 DK DK01914376T patent/DK1255752T3/da active
- 2001-02-15 KR KR1020027010706A patent/KR100713960B1/ko active IP Right Grant
- 2001-02-15 HU HU0204433A patent/HU228979B1/hu active Protection Beyond IP Right Term
- 2001-02-15 ME MEP-2008-530A patent/ME00415B/me unknown
- 2001-02-15 AT AT01914376T patent/ATE369359T1/de active
- 2001-02-15 ES ES01914376T patent/ES2290117T3/es not_active Expired - Lifetime
- 2001-02-15 EA EA200200862A patent/EA005996B1/ru not_active IP Right Cessation
- 2001-02-15 PL PL361209A patent/PL211834B1/pl unknown
- 2001-02-15 MY MYPI20010696A patent/MY130363A/en unknown
- 2001-02-15 AU AU3977001A patent/AU3977001A/xx active Pending
- 2001-02-15 EP EP01914376A patent/EP1255752B1/fr not_active Expired - Lifetime
- 2001-02-15 IL IL15112701A patent/IL151127A0/xx active Protection Beyond IP Right Term
- 2001-02-15 UA UA2002097427A patent/UA73976C2/uk unknown
- 2001-02-15 PE PE2001000172A patent/PE20011083A1/es active IP Right Grant
- 2001-02-15 US US09/783,264 patent/US6573293B2/en not_active Expired - Lifetime
- 2001-02-15 MX MXPA02008021A patent/MXPA02008021A/es active IP Right Grant
- 2001-02-15 JP JP2001560198A patent/JP3663382B2/ja not_active Expired - Lifetime
- 2001-02-15 AU AU2001239770A patent/AU2001239770B2/en not_active Expired
- 2001-02-15 CZ CZ20023081A patent/CZ303705B6/cs unknown
- 2001-02-15 NZ NZ520640A patent/NZ520640A/en not_active IP Right Cessation
- 2001-02-15 DE DE122010000004C patent/DE122010000004I1/de active Pending
- 2001-02-15 CA CA002399358A patent/CA2399358C/fr not_active Expired - Lifetime
- 2001-02-15 BR BRPI0117360A patent/BRPI0117360B8/pt not_active IP Right Cessation
- 2001-02-15 SI SI200130778T patent/SI1255752T1/sl unknown
- 2001-02-15 BR BR0108394-5 patent/BRPI0108394B8/pt not_active IP Right Cessation
- 2001-02-15 PT PT01914376T patent/PT1255752E/pt unknown
- 2001-02-15 RS YUP-614/02A patent/RS50444B/sr unknown
- 2001-02-15 SK SK1326-2002A patent/SK287142B6/sk not_active IP Right Cessation
- 2001-02-15 WO PCT/US2001/004813 patent/WO2001060814A2/fr active Application Filing
- 2001-07-04 TW TW090103496A patent/TWI306860B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 NO NO20023831A patent/NO325532B1/no not_active IP Right Cessation
- 2002-08-13 IS IS6501A patent/IS2491B/is unknown
- 2002-09-10 BG BG107078A patent/BG65764B1/bg unknown
- 2002-09-13 HR HR20020751A patent/HRP20020751B1/xx not_active IP Right Cessation
-
2003
- 2003-04-14 US US10/412,690 patent/US20040063773A1/en not_active Abandoned
- 2003-05-12 HK HK03103304A patent/HK1051188A1/xx not_active IP Right Cessation
-
2005
- 2005-01-04 US US11/028,477 patent/US7125905B2/en not_active Expired - Lifetime
-
2006
- 2006-09-06 US US11/517,529 patent/US7572924B2/en not_active Expired - Lifetime
-
2007
- 2007-09-13 CY CY20071101186T patent/CY1108032T1/el unknown
-
2008
- 2008-01-08 NL NL300332C patent/NL300332I2/nl unknown
- 2008-01-09 LU LU91407C patent/LU91407I2/fr unknown
- 2008-01-15 FR FR08C0002C patent/FR08C0002I2/fr active Active
- 2008-02-04 LT LTPA2008002C patent/LTC1255752I2/lt unknown
- 2008-02-08 CY CY200800004C patent/CY2008004I2/el unknown
- 2008-12-08 NO NO2008019C patent/NO2008019I2/no unknown
-
2009
- 2009-12-29 NL NL300430C patent/NL300430I2/nl unknown
-
2010
- 2010-02-09 NO NO2010002C patent/NO2010002I2/no unknown
- 2010-02-11 BE BE2010C009C patent/BE2010C009I2/fr unknown
- 2010-03-03 LU LU91657C patent/LU91657I2/fr unknown
- 2010-03-09 CY CY2010004C patent/CY2010004I2/el unknown
-
2012
- 2012-01-09 CR CR20120009A patent/CR20120009A/es unknown
- 2012-01-09 CR CR20120007A patent/CR20120007A/es unknown
-
2019
- 2019-02-05 NO NO2019005C patent/NO2019005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK287142B6 (sk) | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie | |
KR100884858B1 (ko) | 단백질 키나제 억제제로서의3-(4-아미도피롤-2-일메틸리덴)-2-인돌리논 유도체 | |
US7053113B2 (en) | Mannich base prodrugs of 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives | |
US20040138269A1 (en) | Substituted pyrroles as kinase inhibitors | |
US6635640B2 (en) | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | |
AU2001239770A1 (en) | Pyrrole substituted 2-indolinone protein kinase inhibitors | |
US7053114B2 (en) | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of an spc |
Free format text: PRODUCT NAME: SUNITINIB MALAT; REGISTRATION NO/DATE: EU/1/06/347/001 - EU/1/06/347/003 20060719 Spc suppl protection certif: 86 5004-2010 Filing date: 20100409 Free format text: PRODUCT NAME: TOCERANIB; REGISTRATION NO/DATE: EU/2/09/100/001 - EU/2/09/100/003 20090923 Spc suppl protection certif: 84 5005-2010 Filing date: 20100409 |
|
SPCG | Grant of an spc |
Free format text: PRODUCT NAME: SUNITINIB MALAT; REGISTRATION NO/DATE: EU/1/06/347/001 - EU/1/06/347/003 20060719 Spc suppl protection certif: 86 5004-2010 Filing date: 20100409 Expiry date: 20210216 Extension date: 20210719 Free format text: PRODUCT NAME: TOCERANIB; REGISTRATION NO/DATE: EU/2/09/100/001 - EU/2/09/100/003 20090923 Spc suppl protection certif: 84 5005-2010 Filing date: 20100409 Expiry date: 20210216 Extension date: 20240923 |
|
SPCY | Application to extend an spc |
Free format text: PRODUCT NAME: SUNITINIB MALAT; REGISTRATION NO/DATE: EU/1/06/347/001 - EU/1/06/347/003 20060724 Spc suppl protection certif: 86 5004-2010 Filing date: 20190212 |
|
SPCZ | Extension of validity of an spc |
Free format text: PRODUCT NAME: SUNITINIB MALAT; REGISTRATION NO/DATE: EU/1/06/347/001 - EU/1/06/347/003 20060724 Spc suppl protection certif: 86 5004-2010 Filing date: 20190212 Extension date: 20220124 |
|
TC4A | Change of owner's name |
Owner name: PHARMACIA & UPJOHN COMPANY, KALAMAZOO, MI, US Effective date: 20200807 Owner name: SUGEN LLC, NEW YORK, NEW YORK, US Effective date: 20200807 |
|
MK4A | Patent expired |
Expiry date: 20210215 |
|
SPCE | Expiry of an spc |
Spc suppl protection certif: 86 5004-2010 Effective date: 20220124 |